• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• Schering Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Thera ...
  Sun, 14 December 2008
  Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for use in previously untreated patients 3 years of age and older with chronic hepatitis C. This repre ...
• Study Showed New Episodes Of Depression Delayed In People Taking Duloxetine
  Sun, 14 December 2008
  Duloxetine hydrochloride (Cymbalta/Xeristar), administered at 60 to 120 mg once daily, delayed the onset of a new episode of depression in patients with recurrent depressive disorder, compared with placebo (p
• Schering-Plough Announces FDA Approval Of PEGINTRON(TM) And REBETOL(R) Combination Thera ...
  Sun, 14 December 2008
  First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon al ...
• Herceptin Given Prior To Surgery Improves The Chance Of Survival Without Relapse For Wom ...
  Sun, 14 December 2008
  Standard one year Herceptin treatment provides long-term benefit to patients with high risk of recurrence About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surgery, compared to only ar ...
• Strength In Genetic Research Example Of University Of Houston's Ability To Solve Challen ...
  Sun, 14 December 2008
  In a move that demonstrates the commercial appeal of research coming out of the University of Houston, a local company created by six of its professors was sold to a global conglomerate in the disease-research and drug-discovery industries. VisiGen Biotechnologies Inc., a biotechnology company created by UH researchers wo ...
• Massachusetts Proposes New Rules Governing Sales/Marketing Tactics Of Pharma And Medical ...
  Sat, 13 December 2008
  The Massachusetts Public Health Council (PHC) today released proposed regulations that will put Massachusetts at the forefront of regulating sales and marketing practices of the pharmaceutical and medical device industry. The new rules will also mandate broad public disclosure of fees, payments and other compensation by comp ...
• Cutting Edge Information Report Analyzes Sales Force Restructuring And Outlines Path Goi ...
  Sat, 13 December 2008
  Pharmaceutical companies have slashed more than 6,000 U.S. sales reps from their ranks in 2008, and additional field sales force cutbacks are expected in early 2009 as companies continue to implement cost-cutting measures. These cutbacks come on the heels of several studies showing that oversized field sales forc ...
• PhRMA Announces Updated Voluntary Restrictions On Direct-To-Consumer Advertising
  Sat, 13 December 2008
  The Pharmaceutical Research and Manufacturers of America on Wednesday announced an updated set of voluntary guidelines on direct-to-consumer drug advertising, but some lawmakers and critics said the new standards do not go far enough to address their concerns, the
• New Data Show Zometa(R) Enhances Impact Of Chemotherapy On Reducing Breast Tumor Size
  Sat, 13 December 2008
  New data released demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.
• CVBT Opens Two Additional Sites For Patient Enrollment For Phase II Heart Trial
  Sat, 13 December 2008
  CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Minneapolis Heart Institute Foundation in Minneapolis MN, and Princ ...